Characterization of human epidermal growth factor receptor and c-Src interactions in human breast tumor cells
- PMID: 9585256
- DOI: 10.1002/(sici)1098-2744(199804)21:4<261::aid-mc5>3.0.co;2-n
Characterization of human epidermal growth factor receptor and c-Src interactions in human breast tumor cells
Abstract
In C3H/10T1/2 murine fibroblasts, overexpression of both c-Src and the human epidermal growth factor (EGF) receptor 1 (HER1) is required for detection of stable complexes between the two molecules and results in hyperactivation of the receptor and synergistic increases in tumor formation in nude mice, as compared with cells that overexpress only one of the pair. Elevated levels or activities of c-Src and HER1 also occur in a subset of later-stage breast cancers, suggesting that interactions between these two molecules could contribute to a more aggressive clinical course. To determine whether stable complexes between c-Src and HER1 occur in human breast cancers under the same conditions as in murine fibroblasts and whether the appearance of such complexes correlates with enhanced signaling through the EGF receptor and increased tumor growth, human breast tumor cell lines and tumor tissues were analyzed for a number of c-Src/HER1-mediated signaling events and tumorigenicity. In a panel of 14 cell lines, 10 overexpressed c-Src, and of these, five contained elevated levels of HER1 and exhibited an EGF-dependent association between HER1 and c-Src. This association was also present in a HER1/c-Src-overexpressing tumor sample from a breast cancer patient. Further analysis of signaling events revealed that phosphorylation of the HER1 substrate, Shc, and its downstream effector, mitogen-activated protein kinase, was increased in EGF-stimulated MDA-MB-468, MDA-MB-231, and BT-549 cells (which overexpress both c-Src and HER1) as compared with MCF7 and ZR-75-1 cells (which only overexpress c-Src). Furthermore, MDA-MB-468 and MDA-MB-231 cells displayed increased tumorigenicity in nude mice. These results support the hypothesis that c-Src/HER1 interactions contribute to tumor progression in certain late-stage breast tumor cells.
Similar articles
-
c-Src-mediated phosphorylation of the epidermal growth factor receptor on Tyr845 and Tyr1101 is associated with modulation of receptor function.J Biol Chem. 1999 Mar 19;274(12):8335-43. doi: 10.1074/jbc.274.12.8335. J Biol Chem. 1999. PMID: 10075741
-
STAT5b, a Mediator of Synergism between c-Src and the Epidermal Growth Factor Receptor.J Biol Chem. 2003 Jan 17;278(3):1671-9. doi: 10.1074/jbc.M207289200. Epub 2002 Nov 11. J Biol Chem. 2003. PMID: 12429742
-
Role of c-Src tyrosine kinase in EGF-induced mitogenesis.Front Biosci. 1997 Oct 15;2:d501-18. doi: 10.2741/a208. Front Biosci. 1997. PMID: 9331427 Review.
-
Epidermal growth factor receptor (HER1) tyrosine kinase inhibitor ZD1839 (Iressa) inhibits HER2/neu (erbB2)-overexpressing breast cancer cells in vitro and in vivo.Cancer Res. 2001 Dec 15;61(24):8887-95. Cancer Res. 2001. PMID: 11751413
-
Functional implication of the interaction between EGF receptor and c-Src.Front Biosci. 2003 Jan 1;8:s28-38. doi: 10.2741/980. Front Biosci. 2003. PMID: 12456372 Review.
Cited by
-
TCPTP regulates SFK and STAT3 signaling and is lost in triple-negative breast cancers.Mol Cell Biol. 2013 Feb;33(3):557-70. doi: 10.1128/MCB.01016-12. Epub 2012 Nov 19. Mol Cell Biol. 2013. PMID: 23166300 Free PMC article.
-
SRC drives growth of antiestrogen resistant breast cancer cell lines and is a marker for reduced benefit of tamoxifen treatment.PLoS One. 2015 Feb 23;10(2):e0118346. doi: 10.1371/journal.pone.0118346. eCollection 2015. PLoS One. 2015. PMID: 25706943 Free PMC article.
-
c-Src and EGFR Inhibition in Molecular Cancer Therapy: What Else Can We Improve?Cancers (Basel). 2020 Jun 7;12(6):1489. doi: 10.3390/cancers12061489. Cancers (Basel). 2020. PMID: 32517369 Free PMC article. Review.
-
Spatiotemporal regulation of Src and its substrates at invadosomes.Eur J Cell Biol. 2012 Nov-Dec;91(11-12):878-88. doi: 10.1016/j.ejcb.2012.06.003. Epub 2012 Jul 22. Eur J Cell Biol. 2012. PMID: 22823952 Free PMC article. Review.
-
Systematic understanding of anti-tumor mechanisms of Tamarixetin through network and experimental analyses.Sci Rep. 2022 Mar 10;12(1):3966. doi: 10.1038/s41598-022-07087-6. Sci Rep. 2022. PMID: 35273218 Free PMC article.
Publication types
MeSH terms
Substances
Grants and funding
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical
Research Materials
Miscellaneous